Home
overview

SMi's 16th annual European Pharmaceutical Pricing and Reimbursement Conference will address key issues such as market access, health technology assessment (HTA), risk management and competition law. Attendees will be shown how to develop a comprehensive pricing and reimbursement strategy which ensures efficiency, value and transparency. With exclusive presentations on the latest P&R developments relevant for Europe and the chance to meet key industry players, this conference will allow attendees to learn, make connections and explore new ideas all at once.

There will also be a half-day pre-conference workshop on Economic Evaluations in Clinical Trials. The interactive environment will allow attendees to explore strategies on how to optimally use randomised clinical trials for economic data collection and economic evaluation.

 


View the conference programme                 Download the brochure              Register for the event

 


  

  

Key topics on the agenda at this year's conference include:

  • Country-specific updates on pricing policies within selected EU member states
  • Market access, brand planning and patient access
  • Key provisions of the EU Transparency Directive
  • Health technology assessment and Outcomes research
  • Regional stakeholder relationships
  • Reimbursement schemes and risk sharing agreements

 

 

KOL 1     

Hear about patient access schemes and flexible pricing

Identify change drivers in pricing and reimbursement practice

Determine how to secure market access and optimal pricing of a product portfolio

Understand regulation of pricing in relation to the EU transparency directive 

Explore macroeconomic factors affecting pricing

 

 

This conference is relevant for anyone working in the following areas:

  • Pricing and reimbursement
  • Market access
  • Health technology assessment
  • Health economics
  • Government affairs 
  • Portfolio management
  • Finance
  • Health outcomes
  • Parallel trade
  • Public affairs
  • Payer relationship management
  • Corporate strategy
  • Sales and Marketing
  • Branding
  • Regulatory Affairs
  • Stakeholder management

 

Conference programme

8:30 Registration & coffee

9:00 Chairman's opening remarks

Colin Wight

Colin Wight, Chief Executive, GalbraithWight

9:10 The new pricing and reimbursement of pharmaceuticals in Italy

Fabrizio Gianfrate

Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara

  • Budget caps and payback from companies for retail and hospital channels
  • Risk sharing and payment by result approach
  • Reference price for off-patent drugs
  • Programme agreements between drug agency AIFA and companies
  • 9:50 Building company-wide market access capabilities from global to local

    Colin Wight

    Colin Wight, Chief Executive, GalbraithWight

  • Understanding the true role of market access
  • Building market access into R&D decision gates
  • Building market access into Brand planning
  • Innovations in market access
  • 10:30 Patient access schemes and flexible pricing – a UK perspective

    Martin Brown

    Martin Brown, Head of Health Economics and Outcomes Research, Novartis Pharmaceuticals

  • Setting a cost-effective price level and  health technology assessment
  • Patient access schemes and flexible pricing
  • Market access decisions
  • Value-based pricing and planning for success
  • 11:10 Morning coffee

    11:30 Recent developments on drug policy in The Netherlands

    Ad Schuurman

    Ad Schuurman, Head of Reimbursement, College Voor Zorgverzekeringen (CVZ)

  • Preferential reimbursement
  • Expense of conditional reimbursement in hospital drugs and orphan drugs
  • Outcomes research
  • Long term drug policy for Dutch government
  • 12:10 Change drivers in pricing and reimbursement practice

    Jorge Wernli

    Jorge Wernli, Vice President, Vifor Pharma

  • Changing macroeconomic environment countries under economic pressure
  • Evolving stakeholder roles the patient
  • New policy frames Germany, UK and Canada
  • P&R evaluation price setting and reimbursement mechanisms
  • HTA, value based pricing, shared risk and contracting
  • Increased use of generics and similars perceptions
  • 12:50 Networking lunch

    14:00 PANEL DISCUSSION: Pricing legislation policy diversity in EU member states

    Frank Thoss

    Frank Thoss, Lawyer, Strategic Policy Affairs, German Association of Research-Based Pharmaceutical Companies

    Richard Lomas

    Richard Lomas, National Commissioning Specialist, Genzyme Therapeutics

    Trevor Leighton

    Trevor Leighton, Vice President, Pricing and Reimbursement, Shire Pharmaceuticals

    Neil Palmer

    Neil Palmer, President and Principal Consultant, PDCI Market Access

    Fabrizio Gianfrate

    Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara

    14:40 Case studies of the use of real-world evidence in drug pricing and reimbursement decisions

    Dhinagar Subramanian

    Dhinagar Subramanian, Associate Director, Global Health Economics and Reimbursement, Ethicon

  • What is real-world evidence?
  • Why real-world evidence is increasingly important for P&R decisions
  • Case studies involving real-life data useage in drug P&R decisions
  • Implications for manufacturers
  • 15:20 The patient's role in market access in public healthcare systems

    Bertram Häussler

    Bertram Häussler, Chairman of the Board of Management, IGES Institut, Berlin

  • Increasing patient choices in an equitable way
  • Patient-reported outcome measures
  • Achieving maximum levels of patient and market access
  • 16:00 Chairman's closing remarks and close of day one

    16:10 Afternoon tea

    8:30 Re-registration & coffee

    9:00 Chairman's opening remarks

    Richard Lomas

    Richard Lomas, National Commissioning Specialist, Genzyme Therapeutics

    9:10 Regional stakeholder relationships: steps to market access

    Richard Lomas

    Richard Lomas, National Commissioning Specialist, Genzyme Therapeutics

  • Understanding challenges facing regional healthcare provider units
  • How is pharma meeting the market access challenges in the UK?
  • Approaches to building trust, access and value
  • 9:50 Canada: outlook for pricing and reimbursement

    Neil Palmer

    Neil Palmer, President and Principal Consultant, PDCI Market Access

  • Overview of Canadian health care system and pharmaceutical funding
  • Price regulation and the new leadership at the Patented Medicine Prices Review Board (PMPRB)
  • Common Drug Review (CDR), reimbursement schemes and listing (risk sharing) agreements
  • National implications of the Ontario 25% pricing rule for generics
  • Impact of the new HTA agencies: pCODR for oncology drugs, INESSS in Quebec
  • 10:30 Morning coffee

    11:00 Expected changes in price setting systems in major economies

    Timothy Lenehan

    Timothy Lenehan, Associate Director, Global Pricing, UCB

  • What changes are expected in the coming 12 months?
  • How will these changes affect the industry?
  • What actions, if any, can industry take?
  • What are implications for companies?
  • 11:40 Regulation of pricing and reimbursement in relation to the EU Transparency Directive

    James Killick

    James Killick, Partner, White & Case LLP

  • Key provisions of the Transparency Directive, as interpreted by the European Court of Justice
  • Complaints to the European Commission to ensure respect for the Transparency Directive
  • The forthcoming revision of the Transparency Directive: when, what and by whom?
  • Other EU initiatives in relation to pharmaceutical pricing and reimbursement
  • 12:20 Networking lunch

    13:50 Reference Price Groups

    Trevor Leighton

    Trevor Leighton, Vice President, Pricing and Reimbursement, Shire Pharmaceuticals

  • Varied approaches & EU deployment
  • Benchmarking international prices
  • Assessing long term impact on innovation
  • Options for industry
  • 14:30 Turkey: outline of pricing and reimbursement systems

    Toros Sahin

    Toros Sahin, Pricing and Reimbursement Coordinator, Sanofi-Aventis

  • General overview of Turkish healthcare environment – latest hurdles for market access
  • Pricing system – overview of past and future
  • Possible risks after access to EU
  • Criteria for reimbursement – a general outline and payers perspective
  • Possible future challenges regarding the P&R system in Turkey
  • 15:10 Performance-based agreements: to engage or not to engage?

    Oscar Leeuwenwkamp

    Oscar Leeuwenwkamp, Director, Market Access and Health Economics, Movetis

  • Current trends in NICE appraisals and the UK
  • Principles of performance based agreements
  • Opportunities and potential risks
  • Mitigating the risks for the industry and funding bodies
  • 15:50 Chairman's closing remarks

    16:00 Afternoon tea and close of conference

    +

    Workshops

    Economic Evaluations in Clinical Trials
    Workshop

    Economic Evaluations in Clinical Trials

    Hilton Munich City
    26th October 2010
    Munich, Germany

    Hilton Munich City

    Rosenheimer Strasse 15
    Munich 81667
    Germany

    Hilton Munich City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.